1. Home
  2. Directory
  3. Illinois
  4. Zion
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1932467792

TEJA POOSARLA M.D.
Prescription History 1932467792
Internal Medicine - Medical Oncology in Zion, IL


Quality Rating: 81.28 out of 100 score

NPI Status: Active since May 01, 2012

Contact Information

2520 ELISHA AVENUE
ZION, IL
ZIP 60099
Phone: (800) 322-9183
Fax: (571) 472-1294

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for TEJA POOSARLA M.D., an active Medical Oncology specialist practicing in Zion, IL. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 203 documented patient claims. Among these therapy options, the most frequently utilized medication is Letrozole, which accounts for 143 claims alone.

Medication Index

A
E
I
L
O
No matching medications currently found on file.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 20
30-Day Fills 48.0
Days Supply 1,440
IL State Average Benchmarks
Peer Average Claims76.0
Peer Average 30-Day Fills183.3
Peer Average Days Supply5,443
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 73.7% less volume than the regional standard for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $982.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$49.13

State Avg Cost Per Claim

$26.77

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Exemestane

Generic Formulation: ExemestaneSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 17
30-Day Fills 33.0
Days Supply 990
IL State Average Benchmarks
Peer Average Claims30.0
Peer Average 30-Day Fills62.3
Peer Average Days Supply1,849
Conservative Utilization

This provider writes prescriptions for this formulation 43.3% less frequently than the standard regional baseline metric for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,554.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$150.28

State Avg Cost Per Claim

$285.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Exemestane is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Exemestane decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers. Exemestane is usually not used in women of childbearing age.

Ibrance

Generic Formulation: PalbociclibSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 252
IL State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills28.2
Peer Average Days Supply782
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.6% less volume than the regional standard for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $128,836.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$10,736.35

State Avg Cost Per Claim

$15,194.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Palbociclib is used to treat a certain type of breast cancer. It works by slowing or stopping the growth of cancer cells.

Letrozole

Generic Formulation: LetrozoleSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 143
30-Day Fills 343.5
Days Supply 10,298
IL State Average Benchmarks
Peer Average Claims54.0
Peer Average 30-Day Fills125.5
Peer Average Days Supply3,733
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 164.8% higher than the standard regional baseline profile for IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,033.19 across this reporting matrix range.

Provider Avg Cost Per Claim

$42.19

State Avg Cost Per Claim

$28.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Ondansetron Hcl

Generic Formulation: Ondansetron HclSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 130
IL State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills33.8
Peer Average Days Supply409
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 66.7% less volume than the regional standard for practitioners inside IL. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $76.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$6.94

State Avg Cost Per Claim

$6.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. It works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like TEJA POOSARLA M.D. provides transparency into local medical care patterns within Zion, IL.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Medical Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.